SHP 654

Drug Profile

SHP 654

Alternative Names: BAX 888; FVIII gene therapy; SHP654

Latest Information Update: 28 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxalta
  • Developer Shire
  • Class Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia A

Most Recent Events

  • 25 Oct 2017 SHP 654 receives Orphan Drug status for Haemophilia A in USA
  • 25 Oct 2017 US FDA approves IND application for SHP 654 in Haemophilia A
  • 25 Oct 2017 Shire plans a phase I/II trial for Haemophilia A worldwide by end of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top